Minervax ApS

Minervax ApS is a biotechnology company headquartered in Denmark, founded in 2010. The company aims to develop a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threatening infections caused by Group B streptococcus (GBS). Their slogan "Developing a maternal vaccine for Group B Streptococcus" reflects their primary goal. GBS is a significant concern, being the leading cause of life-threatening infections in newborns and responsible for substantial negative outcomes in pregnancies globally. MinervaX's vaccine is based on adjuvanted proteins antigens, covering close to 100% of clinical GBS isolates, which shows promising potential. The annual impact of GBS is substantial, with 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage worldwide. This demonstrates the urgent need for an effective solution. The latest significant development for MinervaX is the €54.00M Venture Round investment on 11 October 2023. The investors involved in this round are Novo Holdings, Industrifonden, Sunstone Capital, OrbiMed, Wellington Partners, Adjuvant Capital, BB Pureos Bioventures, Sanofi Ventures, Trill Impact Ventures, and LF Investment, which highlights the confidence and support from key players in the industry. Overall, MinervaX's focus on addressing a critical healthcare challenge through innovative biotechnology, coupled with robust investor support, positions them as a compelling investment opportunity with the potential for significant social and financial impact.